



MINISTERIO
DE SANIDAD, SERVICIOS SOCIALES
E IGUALDAD

am agencia española de
medicamentos y
productos sanitarios

DEPARTAMENTO DE
MEDICAMENTOS
VETERINARIOS

Agencia Española de Medicamentos y Productos Sanitarios

C/Campezo 1, Edificio 8
28022 – Madrid
España
(Reference Member State)

DECENTRALISED PROCEDURE

[DRAFT] PUBLICLY AVAILABLE ASSESSMENT REPORT FOR A VETERINARY MEDICINAL PRODUCT

ANTISHMANIA 300 mg/ml, solution for injection for dogs

CORREO ELECTRÓNICO

mresvet@aemps.es

13876.DOCX

F-DMV-25-01

C/ CAMPEZO, 1 – EDIFICIO 8
28022 MADRID
TEL: 91 822 54 01
FAX: 91 822 5443



MODULE 1

PRODUCT SUMMARY

EU Procedure number	ES/V/0232/001/ DC
Name, strength and pharmaceutical form	ANTISHMANIA 300 mg/ml, solution for injection for dogs
Applicant	SUPPORT PHARMA, S.L. General Alvarez de Castro, 39 28010 Madrid, Spain
Active substance(s)	Meglumine antimoniate
ATC Vet code	QP51AB01
Target species	Dogs
Indication for use	Symptomatic treatment of canine leishmaniosis.



MODULE 2

The Summary of Product Characteristics (SPC) for this product is available on the Heads of Medicines Agencies website (<http://www.hma.eu>).

MODULE 3

PUBLIC ASSESSMENT REPORT

Legal basis of original application	Decentralised application in accordance with Article 13(1) of Directive 2001/82/EC as amended.
Date of completion of the original decentralised procedure	17/12/2015
Date product first authorised in the Reference Member State (MRP only)	N/A
Concerned Member States for original procedure	EL & FR

I. SCIENTIFIC OVERVIEW

For public assessment reports for the first authorisation in a range:

The product is produced and controlled using validated methods and tests, which ensure the consistency of the product released on the market.

It has been shown that the product can be safely used in the target species; the reactions observed are indicated in the SPC.

The product is safe for the user, and for the environment, when used as recommended. Suitable warnings and precautions are indicated in the SPC.

The efficacy of the product was demonstrated according to the claims made in the SPC.

The overall risk/benefit analysis is in favour of granting a marketing authorisation.

II. QUALITY ASPECTS

A. *Composition*

The product contains 300 mg/ml meglumine antimoniate (equivalent to 81 mg/ml Sb⁵⁺) as active substance, and excipients Potassium metabisulphite (E224), Sodium sulphite anhydrous (E221), Sodium hydroxide and Water for injections.

The container/closure system is a type I glass vials of 5 ml with a type I chlorobutyl-based elastomer rubber closure and an aluminium cap fitted with a tamper-evident polypropylene seal. The particulars of the containers and controls performed are provided and conform to the regulation.

The choice of the presence of preservatives are justified.

The product is an established pharmaceutical form and its development is adequately described in accordance with the relevant European guidelines.

B. *Method of Preparation of the Product*

The product is manufactured fully in accordance with the principles of good manufacturing practice from a licensed manufacturing site.

Process validation data on the product have been presented in accordance with the relevant European guidelines.

C. *Control of Starting Materials*

The active substance is meglumine antimoniate an established substance described in the Brazilian Pharmacopoeia. The active substance is manufactured in accordance with the principles of good manufacturing practice.

The active substance specification is considered adequate to control the quality of the material. Batch analytical data demonstrating compliance with this specification have been provided.

The information on the active substance is supplied through an ASMF procedure.

D. *Specific Measures concerning the Prevention of the Transmission of Animal Spongiform Encephalopathies*

There are no substances within the scope of the TSE Guideline present or used in the manufacture of this product.

E. *Control on intermediate products (pharmaceuticals)*

Not applicable.

F. Control Tests on the Finished Product

The finished product specification controls the relevant parameters for the pharmaceutical form. The tests in the specification, and their limits, have been justified and are considered appropriate to adequately control the quality of the product.

Satisfactory validation data for the analytical methods have been provided.

Batch analytical data from the proposed production site have been provided demonstrating compliance with the specification.

G. Stability

Stability data on the active substance have been provided in accordance with applicable European guidelines, demonstrating the stability of the active substance when stored under the approved conditions.

Stability data on the finished product have been provided in accordance with applicable European guidelines, demonstrating the stability of the product throughout its shelf life when stored under the approved conditions.

H. Genetically Modified Organisms

Not applicable.

J. Other Information

Not applicable.

III. SAFETY AND RESIDUES ASSESSMENT (PHARMACOTOXICOLOGICAL)

As this is a generic application according to Article 13 (1) and the product can be considered bioequivalent to the reference product according to condition 7.1 b) of the “Guideline on the conduct of bioequivalence studies for veterinary medicinal products” EMA/CVMP/016/00-Rev.2, results of toxicological, pharmacological or clinical tests are not required.

The safety aspects of this product are identical to the reference product.

Warnings and precautions as listed on the product literature are the same as those of the reference product and are adequate to ensure safety of the product to users and the environment.

III.A Safety Testing

Pharmacological Studies

Since the application has been submitted in accordance with Article 13 (1) (Directive 2001/82/EC, as amended by Directive 2004/28/EC), results of pharmacological tests are not required.

The pharmacological details of this product are the same as those of the reference product.

Meglumine antimoniate is an antileishmanial antiprotozoal agent belonging to the antimoniate group, whose mechanism of action could be linked to the inhibition of certain glycolytic enzymes in the parasite.

Meglumine antimoniate is not absorbed orally while it is absorbed completely (bioavailability > 90%) intramuscularly and subcutaneously.

The tissue distribution of meglumine antimoniate is very limited. The elimination half-life is short (from 20 minutes to 2 hours, depending on the administration route) and it is eliminated rapidly via the urine (over 80% in the first nine hours).

Toxicological Studies

Since the application has been submitted in accordance with Article 13 (1) (Directive 2001/82/EC, as amended by Directive 2004/28/EC), results of toxicological tests are not required.

User Safety

ANTISHMANIA is a generic product of GLUCANTIME. Both products are identical in terms of active substance and pharmaceutical form, and essentially similar in terms of excipients, hence presenting the same risk for the user administering them. Warnings and precautions as listed on the product literature are adequate to ensure safety to users of the product.

Ecotoxicity



The applicant provided a first phase environmental risk assessment in compliance with the relevant guideline which showed that no further assessment is required. The assessment concluded that, since the product is indicated only for dogs, no special risk for the environment is expected.

Warnings and precautions as listed on the product literature are adequate to ensure safety to the environment when the product is used as directed.

III.B Residues documentation

Not applicable.



IV. CLINICAL ASSESSMENT (EFFICACY)

This is a generic application according to Article 13(1) of Directive 2001/82/EC, amended by Directive 2004/28/EC. As bioequivalence with a reference product has been demonstrated, efficacy studies are not required. The efficacy claims for this product are equivalent to those of the reference product.

IV.A Pre-Clinical Studies

As this was a generic application according to Article 13(1) of Directive 2001/82/EC, amended by Directive 2004/28/EC, and Bioequivalence with a reference product was demonstrated, pre-clinical studies are not required.

IV.B Clinical Studies

As this was a generic application according to Article 13(1) of Directive 2001/82/EC, amended by Directive 2004/28/EC, and Bioequivalence with a reference product was demonstrated, clinical studies are not required.



V . OVERALL CONCLUSION AND BENEFIT– RISK ASSESSMENT

The data submitted in the dossier demonstrate that when the product is used in accordance with the Summary of Product Characteristics, the risk benefit profile for the target species is favourable and the quality and safety of the product for humans and the environment is acceptable.

MODULE 4

POST-AUTHORISATION ASSESSMENTS

The SPC and package leaflet may be updated to include new information on the quality, safety and efficacy of the veterinary medicinal product. The current SPC is available on the veterinary Heads of Agencies website (www.hma.eu).

This section contains information on significant changes which have been made after the original procedure which are important for the quality, safety or efficacy of the product.

<None>

or

Complete this section for extensions to the same VPA range or defined, significant variations, using the table shown below.

Some examples of significant changes in safety or efficacy data are:

- *Changes to pharmacokinetic data leading to a change in the SPC*
- *Changes to toxicological data leading to a change in the SPC*
- *Changes to user safety warnings*
- *Changes to ecotoxicological information as given in the SPC or changes to disposal warnings*
- *New residue studies in new target species or tissues*
- *Reassessment of residue data or new studies resulting from changes to MRL*
- *Changes to withdrawal period*
- *Changes to target species*
- *Changes to target species tolerance data leading to change in warnings/precautions for target species*
- *New or changed indications*

Significant changes in administrative or quality data include any Type II change, which affects the initial report. The following Type IA or IB changes may also apply:

- *Name of product [Type IA: 2]*
- *Name of active substance [Type IA: 3]*
- *MAH [Type IA: 1]*
- *Composition of the medicinal product [Type IB: 18, Type IA/B: 25, 34, 35, 39]*
- *Container/closure system [Type 1/B: 26, 28, 29, 36, 41, 43]*
- *Method of preparation [Type 1B: 33]*
- *Active substance specification [Type IB: 25]*
- *CEP [Type IA/B: 15]*
- *Re-test period or storage conditions of active substance [Type IB: 17]*
- *Excipient specifications [Type 1A/B: 25]*
- *Packaging materials [Type 1A/B: 28, 29, 36, 41, 43]*
- *TSE [Type 1A: 16, 22]*
- *Shelf-life or storage conditions of the finished product [Type 1B: 42]*

Quality changes

Summary of change (Application number)	Section updated in Module 3	Approval date
<Example: Change to active substance specification> (MS/V/XXX/X/IB/XX)	N/A	

Safety/efficacy changes

Summary of change (Type; application number)	Section updated in Module 3	Approval date
<Example: Addition of target species - pigs> (MS/V/XXX/X/II/XX)	<IIIA> <IIIB> <IV>	